[u'-----BEGIN PRIVACY-ENHANCED MESSAGE-----\nProc-Type: 2001,MIC-CLEAR\nOriginator-Name: webmaster@www.sec.gov\nOriginator-Key-Asymmetric:\n MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen\n TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB\nMIC-Info: RSA-MD5,RSA,\n WWk0zETQMcG9eo8mtzXCQQGe7Jw/qq6W2Dy/Mt6N/O9hKlaLAVI0W4fWfMFq7n0g\n tsEIMRdpWYpGIpKtx1NaLQ==\n\n', u'0001035704-04-000565.txt : 20040927\n', u'0001035704-04-000565.hdr.sgml : 20040927\n', u'20040927133722\nACCESSION NUMBER:\t\t0001035704-04-000565\nCONFORMED SUBMISSION TYPE:\t8-K\nPUBLIC DOCUMENT COUNT:\t\t2\nCONFORMED PERIOD OF REPORT:\t20040927\nITEM INFORMATION:\t\tResults of Operations and Financial Condition\nITEM INFORMATION:\t\tFinancial Statements and Exhibits\nFILED AS OF DATE:\t\t20040927\nDATE AS OF CHANGE:\t\t20040927\n\nFILER:\n\n\tCOMPANY DATA:\t\n\t\tCOMPANY CONFORMED NAME:\t\t\tPHARMION CORP\n\t\tCENTRAL INDEX KEY:\t\t\t0001203866\n\t\tSTANDARD INDUSTRIAL CLASSIFICATION:\tPHARMACEUTICAL PREPARATIONS [2834]\n\t\tIRS NUMBER:\t\t\t\t000000000\n\n\tFILING VALUES:\n\t\tFORM TYPE:\t\t8-K\n\t\tSEC ACT:\t\t1934 Act\n\t\tSEC FILE NUMBER:\t000-50447\n\t\tFILM NUMBER:\t\t041046716\n\n\tBUSINESS ADDRESS:\t\n\t\tSTREET 1:\t\t2525 28TH STREET\n\t\tCITY:\t\t\tBOULDER\n\t\tSTATE:\t\t\tCO\n\t\tZIP:\t\t\t80301\n\t\tBUSINESS PHONE:\t\t720 564 9100\n', u'\n', u'\n', u'8-K\n', u'1\n', u'd18704e8vk.htm\n', u'FORM 8-K\n', u'\n', u'e8vk', u'\n', u' PAGEBREAK ', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'UNITED STATES', u'\nSECURITIES AND EXCHANGE COMMISSION', u'\n', u'Washington, D.C. 20549', u'\n', u'\n', u'FORM 8-K', u'\n', u'CURRENT REPORT', u'\nPURSUANT TO SECTION 13 OR 15(d) OF THE', u'\nSECURITIES EXCHANGE ACT OF 1934', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Date of Report (Date of earliest event reported)\n', u'\n', u'\xa0', u'\n', u'September\xa027, 2004', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'Pharmion Corporation', u'\n', u'\n', u'(Exact name of registrant as specified in its charter)', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Delaware', u'\n', u'\n', u'\xa0', u'\n', u'000-50447', u'\n', u'\n', u'\xa0', u'\n', u'84-1521333', u'\n', u'\n', u'\n', u'\xa0\n', u'\n', u'\xa0', u'\n', u'\xa0\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(State or other jurisdiction', u'\nof incorporation)\n', u'\n', u'\xa0', u'\n', u'(Commission File', u'\nNumber)\n', u'\n', u'\xa0', u'\n', u'(IRS Employer', u'\nIdentification No.)', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'2525 28th Street, Boulder, Colorado\n', u'\n', u'\xa0', u'\n', u'80301', u'\n', u'\n', u'\n', u'\xa0\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(Address of principal executive offices)\n', u'\n', u'\xa0', u'\n', u'(Zip Code)', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Registrant\x92s telephone number, including area code\n', u'\n', u'\xa0', u'\n', u'720-564-9100', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'\xa0\n', u'\n(Former name or former address if changed since last report)', u'\n', u'\n', u'\n', u'\n', u'\xa0\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Item', u' 2.02', u'\xa0', u'\n', u'Financial Statements, Pro Forma Financial Information and Exhibits', u'\n', u'\n', u'\n', u'(c)\xa0Exhibit\xa099.1 \x97 Press Release dated September\xa027, 2004.\n\n\n\n', u'This exhibit is furnished pursuant to Item\xa012 and shall not be\ndeemed to be \x93filed.\x94\n\n\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Item', u' 9.01', u'\xa0', u'\n', u'Disclosure of Results of Operations and Financial Condition', u'\n', u'\n', u'\n', u'On September\xa027, 2004, the\nPharmion Corporation issued a\npress release updating the\nCompany\x92s 2004 sales and\nearnings guidance. A copy of\nthe press release is attached\nas Exhibit\xa099.1 to this\nCurrent Report on Form 8-K.\nThe information in this Form\n8-K and the exhibit attached\nhereto shall not be deemed\n\x93filed\x94 for purposes of\nSection\xa018 of the Securities\nExchange Act of 1934 (the\n\x93Exchange Act\x94) or otherwise\nsubject to the liabilities of\nthat section, nor shall it be\ndeemed incorporated by\nreference in any filing under\nthe Securities Act of 1933 or\nthe Exchange Act, except as\nshall be expressly set forth\nby specific reference in such\nfiling.\n\n\n', u'SIGNATURES', u'\n', u'\xa0\xa0\xa0\xa0\xa0Pursuant to the requirements of the Securities Exchange Act of 1934,\nthe Registrant has duly caused this report to be signed on its behalf\nby the undersigned hereunto duly authorized.\n\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'PHARMION CORPORATION', u'\n\xa0', u'\n', u'\xa0', u'\n', u'\n', u'Date: 9-27-04\xa0', u'\n', u'By:\xa0\xa0', u'\n', u'/s/ Erle T. Mast', u'\n\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Erle T. Mast\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Chief Financial Officer\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'2\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'EXHIBIT INDEX', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Exhibit No.', u'\n', u'\xa0', u'\n', u'Description', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\xa0', u'\n', u'\n', u'99.1\n', u'\n', u'\xa0', u'\n', u'Press release dated September\xa027, 2004 updating the Company\x92s 2004 sales and earnings guidance.', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'3\n', u'\n', u'\n', u'\n', u'\n', u'EX-99.1\n', u'2\n', u'd18704exv99w1.htm\n', u"PRESS RELEASE DATED SEPTEMBER 27, 2004 UPDATING THE COMPANY'S 2004 SALES AND EARNINGS GUIDANCE.\n", u'\n', u'exv99w1', u'\n', u' PAGEBREAK ', u'\n', u'\xa0', u'\n', u'\n', u'EXHIBIT 99.1', u'\n', u'FOR RELEASE UPON RECEIPT ON SEPTEMBER 27, 2004\n\n\n\n', u'Contact:', u'\nBreanna Burkart/Anna Sussman', u'\nDirectors, Investor Relations and Corporate Communications', u'\nPharmion Corporation', u'\n720-564-9150\n\n\n', u'Pharmion Corporation Increases Vidaza Sales Guidance', u'\n', u'\xa0\xa0\xa0\xa0\xa0BOULDER, Colo., September\xa027, 2004 \x97 Pharmion Corporation (NASDAQ: PHRM)\ntoday reported that it has increased sales guidance for Vidaza for the second\nhalf of 2004 to a range of $40-45\xa0million, from its previous range of $20-27\nmillion, based on greater than anticipated sales in the initial months of its\nVidaza launch.\n\n', u'Vidaza', u'TM', u' (azacitidine for injectable suspension) was launched in the U.S. on\nJuly\xa01, 2004 after receiving a full approval in May from the U.S. Food and Drug\nAdministration (FDA)\xa0for the treatment of all five subtypes of Myelodysplastic\nSyndromes (MDS). These subtypes include: refractory anemia (RA)\xa0or refractory\nanemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or\nthrombocytopenia or requiring transfusions), refractory anemia with excess\nblasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T),\nand chronic myelomonocytic leukemia (CMMoL).\n\n', u'\x93We are pleased that physicians are choosing to use Vidaza in their treatment\nof MDS,\x94 said Patrick Mahaffy, Pharmion\x92s president and chief executive\nofficer. \x93While we caution that it is still too early in the launch to\nestimate the longer-term sales of Vidaza, it is evident from our sales to date\nand our interactions with physicians that Vidaza represents a potentially\nimportant new treatment option for this very difficult-to-treat disease.\x94\n\n\n', u'2004 Financial Outlook', u'\n', u'Pharmion is increasing its net sales expectations for 2004 to a range of\n$111-119\xa0million, up from previous guidance of $91-$101\xa0million, based on\nincreased expectations for sales of Vidaza. The Company now estimates total\nVidaza sales for the second half of 2004 will be in a range of $40-45\xa0million,\nan increase from previous guidance of $20-27\xa0million. Thalidomide sales\nguidance remains in a range of $58-61\xa0million for 2004. With the revised\nguidance for Vidaza sales, the Company now estimates its net loss for 2004 to\nbe in a range of $(0.90) \x97 $(1.10) per share, compared to its previous guidance\nrange of a net loss of $(1.40) \x97 (1.60) per share.\n', u'\n', u'-more-\n\n\n\n', u'\xa0\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'Pharmion Increases Vidaza Sales Guidance for 2004', u'\nPage Two', u'\n', u'About MDS', u'\n', u'MDS is a bone marrow disorder characterized by the production of abnormally\nfunctioning, immature blood cells. The highest prevalence of MDS is in patients\nover 60\xa0years of age. According to the American Cancer Society and the Aplastic\nAnemia and MDS International Foundation, there are an estimated 10,000-30,000\nnew cases of MDS in the United States each year. Survival ranges from six\nmonths to many years for the different subtypes of MDS. MDS can result in death\nfrom bleeding and infection in the majority of patients, and transformation to\nacute myelogenous leukemia (AML)\xa0occurs in up to 40\xa0percent of patients. The\nprognosis for patients transforming to AML is exceptionally poor.\n', u'\n', u'About Pharmion:', u'\n', u'Pharmion is a pharmaceutical company focused on acquiring, developing and\ncommercializing innovative products for the treatment of hematology and\noncology patients in the U.S., Europe and additional international markets. For\nadditional information about Pharmion, please visit the Company\x92s website at\nwww.pharmion.com.\n', u'\n', u'Safe Harbor Statement under the Private Securities Litigation Reform Act of\n1995: ', u'This release contains forward-looking statements, which express the\ncurrent beliefs and expectations of management. Such statements are based on\ncurrent expectations and involve a number of known and unknown risks and\nuncertainties that could cause Pharmion\x92s future results, performance or\nachievements to differ significantly from the results, performance or\nachievements expressed or implied by such forward-looking statements. Important\nfactors that could cause or contribute to such differences include the status\nand timing of regulatory approvals for Thalidomide Pharmion 50mg and Vidaza;\nthe impact of competition from other products under development by Pharmion\x92s\ncompetitors; the regulatory environment and changes in the health policies and\nstructure of various countries; acceptance and demand for new pharmaceutical\nproducts and new therapies, uncertainties regarding market acceptance of\nproducts newly launched, currently being sold or in development; Pharmion\x92s\nability to successfully acquire rights to develop and commercialize additional\npharmaceutical products; fluctuations in currency exchange rates, and other\nfactors that are discussed in Pharmion\x92s filings with the U.S. Securities and\nExchange Commission. Forward-looking statements speak only as of the date on\nwhich they are made, and Pharmion undertakes no obligation to update publicly\nor revise any forward-looking statement, whether as a result of new\ninformation, future developments or otherwise.\n\n\n', u'# # #\n\n\n\n\n', u'\xa0\n', u'\n', u'\n', u'\n', u'\n-----END PRIVACY-ENHANCED MESSAGE-----\n']